MARKET

INCY

INCY

Incyte Corp
NASDAQ
102.52
+2.06
+2.05%
After Hours: 102.55 +0.03 +0.03% 19:33 12/05 EST
OPEN
101.00
PREV CLOSE
100.46
HIGH
103.68
LOW
98.36
VOLUME
2.36M
TURNOVER
--
52 WEEK HIGH
109.28
52 WEEK LOW
53.56
MARKET CAP
20.13B
P/E (TTM)
17.33
1D
5D
1M
3M
1Y
5Y
1D
Incyte Corporation Releases Study on Selective Targeting of CALR Mutant Cells in Myeloproliferative Neoplasms
Reuters · 15h ago
Incyte: Buy At This Inflection Point
Seeking Alpha · 21h ago
Incyte Honors 2025 MPN Heroes at ASH Annual Meeting
Reuters · 1d ago
Trevi Therapeutics Names David Hastings as Chief Financial Officer
Reuters · 2d ago
Top Executive Sells Millions in Incyte Stock!
TipRanks · 3d ago
Incyte EVP & Chief Medical Officer Steven H. Stein Reports Disposal of Common Shares
Reuters · 3d ago
Incyte Corporation Files Initial Beneficial Ownership Statement for Richard A. Hoffman, EVP & General Counsel
Reuters · 3d ago
Incyte Grants Equity Awards to New Executive Vice President Richard Hoffman
Reuters · 3d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.